admin – Page 3405 – Get News Story

Local Roofline Launches Their New Roofing Website to Serve Gainsborough and Surrounding Areas

Pitched Roof Installation in Gainsborough Town

Local Roofline, a leading and trusted roofing company in Gainsborough launches their new website. After years of helping out customers in the area, they can now be found online too.

Gainsborough, UK – May 1, 2025 – Local Roofline, a trusted roofing company with over 20 years of industry experience, has officially launched its new website, www.localroofline.co.uk, offering a full range of professional roofing services across Gainsborough, Scunthorpe, Doncaster, Hull, Rotherham, and Barnsley.

Specialising in new roof installations, flat Roofing Gainsborough solutions, emergency Roof Repair Gainsborough, and chimney stack repairs, Local Roofline is committed to providing high-quality workmanship backed by a 25-year warranty. The company’s expertise covers tiled roofs, rubber roofs, felt flat roofs, and more, with a strong focus on durable results and excellent customer service.

“Our goal at Local Roofline has always been to deliver roofing work that homeowners can trust, without the stress,” said a spokesperson for Local Roofline. “With the launch of our new website, we’re making it even easier for customers to get free quotes, book inspections, and access professional roofing services they can rely on.”

The newly launched website provides detailed information about Local Roofline’s services, customer guarantees, and service areas. Homeowners seeking fast, affordable, and long-lasting roofing solutions can now request a free, no-obligation quote online.

Local Roofline’s services include:

New Roof Installations (pitched and flat roofing)

Emergency Roofing Repairs (fast, reliable call-outs)

Flat Roof Systems (rubber, felt, GRP options)

Chimney Stack Repairs (maintenance, repointing, rebuilds)

Roof Inspections and Surveys

Local Roofline’s team is proud to use premium materials, deliver top-quality craftsmanship, and maintain a strong reputation for professionalism in every project undertaken.

For more information or to request a free roofing quote, visit www.localroofline.co.uk or call Local Roofline today.

Follow Us:

Facebook: https://www.facebook.com/localpatioltd/

Instagram: https://www.instagram.com/local_roofline1997/

Checkatrade: https://www.checkatrade.com/trades/localrooflineandpatioltd

Media Contact
Company Name: Local Roofline
Contact Person: John Haxby
Email: Send Email
Phone: 07737 481470
Address:28A Spiral Terrace Gainsborough
City: Lincolnshire
State: England
Country: United Kingdom
Website: www.localroofline.co.uk

Ultimate Home Solutions Launches Stylish, Affordable Fitted Kitchens in Glasgow from Just £57/Month

Ultimate Home Solutions, a renowned name in home improvement, is excited to introduce its new line of cost-effective fitted Kitchens Glasgow available for Glasgow homeowners starting from just £57 per month. As an extension of their commitment to enhancing living spaces with elegance and utility, Ultimate Home Solutions offers bespoke kitchen designs that combine quality and affordability.

Led by Colin Pass, Ultimate Home Solutions employs a meticulous and customer-centric approach, ensuring every kitchen not only looks exquisite but also functions seamlessly. The expert team provides a full suite of services from custom design and high-quality material sourcing to precise installation, transforming every Kitchen company in Glasgow into a chic focal point of the home.

Understanding the financial commitments of homeowners, Ultimate Home Solutions also offers appealing financing options such as 0% interest-free credit and ‘buy now, pay later’ plans to make dream kitchens accessible to everyone. Coupled with a 25% discount promotion, these kitchens are now more attractive than ever.

“We believe every home should have a kitchen that inspires, and we’re thrilled to make this a reality at such an approachable price point,” said Colin Pass, Owner of Ultimate Home Solutions. “We take pride in delivering kitchens that stand out for both their style and durability.”

By visiting the showroom at 75 Kings Inch Dr, Renfrew, Glasgow, customers can explore a wide range of styles, including contemporary models like Oxford, Vivo, and Cartmel. Ultimate Home Solutions provides complimentary consultations to assist customers in choosing options best suited to their space and lifestyle.

Ultimate Home Solutions also actively contributes to the local community as the official social media sponsor of St. Mirren Football Club, reaffirming its commitment to local engagement and support.

For more information or to schedule a consultation, customers are encouraged to reach out via the company website or by calling 0800 029 3875.

Media Contact
Company Name: Ultimate Home Solutions Ltd
Contact Person: Colin Pass
Email: Send Email
Phone: 0800 029 3875
Address:Unit 9, 140 Woodhead Road, Nitshill
City: Glasgow
Country: Scotland
Website: www.ultimatehomesolutions.co.uk/kitchens-glasgow/

Jim Phillips, SVP – Managing Director of BRB Wealth Interviewed on The influential Entrepreneur Podcast Discussing Long Term Care

Jim Phillips discusses the importance of long-term care

Listen to the interview on the Business Innovators Radio Network: Jim Phillips, SVP – Managing Director of BRB Wealth, Discussing Long Term Care

Jim Phillips, the managing director of BRB Wealth, shares his journey starting from Merrill Lynch to his current role. He discusses the advantages of working in a community bank environment compared to larger wire houses, emphasizing the importance of building personal relationships with clients.

Long-term care (LTC) is a critical aspect of financial planning that many individuals overlook until it’s too late. Jim explained the significance of long-term care was thoroughly discussed, shedding light on its definition, necessity, and the misconceptions surrounding it.

Long-term care refers to a range of services and support for individuals who experience chronic illnesses or disabilities that limit their ability to perform basic activities of daily living (ADLs).

To qualify for long-term care benefits, an individual must be unable to perform at least two of these six activities. This care can take various forms, from in-home assistance to nursing facilities, depending on the individual’s needs.

Many people may dismiss the idea of needing long-term care, believing it won’t happen to them. However, statistics reveal a different story. Jim shared that approximately 70% of individuals aged 65 and older will require some form of long-term care support. This statistic is further emphasized by Jim’s personal experience, where 75% of his and his wife’s parents needed long-term care at some point.

There are some misconceptions that people have regarding long-term care:

Health Insurance Coverage: Many believe that their regular health insurance will cover long-term care costs. However, traditional health insurance typically does not cover these expenses.

Medicaid as a Safety Net: Some individuals think they can rely on Medicaid for long-term care. While Medicaid does cover long-term care, it often requires individuals to be destitute, which may not be an ideal situation.

Long-Term Care Insurance: A prevalent misconception is that long-term care insurance works like other insurance policies, where premiums are paid, and benefits are received when needed. Many people fear wasting money on premiums if they never need care, leading them to avoid purchasing coverage altogether.

Jim emphasized the importance of planning for long-term care well in advance. Ideally, individuals should start considering their long-term care options in their 50s or 60s when they are still healthy and can qualify for benefits. Waiting too long can lead to regrets, especially if health issues arise that prevent individuals from obtaining coverage.

Jim shared insights from a survey indicating that one of the top financial regrets among individuals over 50 is not purchasing long-term care insurance. This highlights the necessity of addressing long-term care in financial planning to avoid potential financial strain during retirement.

Jim shared: “I act as a Financial Director, focusing on helping clients manage risk in their financial lives.”

Video Link: https://www.youtube.com/embed/NYR1O3pSKFw

About Jim Phillips

Jim has over 30 years of investment and wealth management experience. Jim started his career with Merrill Lynch in Richmond, and most recently developed and managed the investment program at CB&T Wealth Management. Jim believes in a personalized approach to get to know his clients and their financial goals, and then develops a strategy to work toward achieving them. He helps his clients understand the current financial, economic, and political climate to better position their assets to address their preservation, growth, income, or legacy needs. Jim is a graduate of the University of Florida. He lives in Chesterfield with his wife, Nina. Jim enjoys distance running, travel, and spending time with his family.

Learn More: https://www.mybrb.financial/Wealth

Securities and advisory services are offered through LPL Financial (LPL), a registered investment advisor and broker/dealer (member FINRA/SIPC). Insurance products are offered through LPL or its licensed affiliates. Blue Ridge Bank and BRB Wealth are not registered as a broker/dealer or investment advisor. Registered representatives of LPL offer products and services using BRB Wealth and may also be employees of Blue Ridge Bank. These products and services are being offered through LPL or its affiliates, which are separate entities from and not affiliates of Blue Ridge Bank or BRB Wealth. Securities and insurance offered through LPL or its affiliates are: Not Insured by FDIC or Any Other Government Agency Not Bank Guaranteed Not Bank Deposits or Obligations May Lose Value

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

Revolutionising Clubbing: Dive into the Sober Rave Experience at the Ministry of Sound

Join Ecstatic Dance London for an Unforgettable Night of Music and Wellness in a Groundbreaking Alcohol and Drug-Free Environment.

Ecstatic Dance London is thrilled to announce its latest Sober Wellness Rave Experience, a vibrant and transformative night of music and wellbeing at the iconic Ministry of Sound, the heartbeat of electronic dance music and rave culture.

This event marks the third iteration of a revolutionary concept that fuses the exhilarating energy of nightclub culture with an uplifting, substance-free environment.

This unique event will take place at the legendary Ministry of Sound, renowned for its unparalleled sound system and rich history in the dance music scene. Attendees can expect an eclectic mix of musical vibes, including Afro-House, Deep & Uplifting House, Drum & Bass, and Melodic Trance, providing the perfect soundtrack for an unforgettable night.

The Sober Wellness Rave Experience is more than just a night out; it is a cultural movement designed to promote a healthy lifestyle while embracing the joy and freedom of dance.

The evening will kick off with an optional Yoga class or choose a powerful breathwork session with Soma Breath founder Niraj Naik, setting the stage for a holistic rave experience. Participants will also be treated to a complimentary Cacao Ceremony and Chai! Plus upstairs there’s a holistic wellbeing area to have mini taster sessions of either multi-handed Lomi Lomi (Hawaiian Massage!) and other massage and relaxation practices, all of this enhancing the evening’s wellness focus.

Ecstatic Dance London, pioneers of the Ecstatic Dance movement in the UK, are excited to bring their innovative concept to the Ministry of Sound, offering club-goers a chance to enjoy the thrill of a rave in a positive and supportive setting.

Tickets are on sale now for this must-attend event. Don’t miss the chance to be a part of the Sober ReLOVEution at the Ministry of Sound!

For more information and tickets, visit: https://www.eventbrite.co.uk/e/sober-rave-ministry-of-sound-ecstatic-dance-conscious-wellness-event-tickets-1297782936699

Media Contact
Company Name: Ecstatic Dance London
Contact Person: Media Manager
Email: Send Email
Country: United Kingdom
Website: https://www.eventbrite.co.uk/e/sober-rave-ministry-of-sound-ecstatic-dance-conscious-wellness-event-tickets-1297782936699

Stanley Targosz, President of The Responsible Brand, Interviewed on The Influential Entrepreneurs Podcast to Discuss Student Loan Myths & Misconceptions

Stanley Targosz discusses Highlights Student Loan Myths & Misconceptions

Listen to the interview on the Business Innovators Radio Network: https://businessinnovatorsradio.com/interview-with-stanley-targosz-president-and-founding-member-of-the-responsible-brand-discussing-student-loan-myths-misconceptions/

Stanley Targosz, the founding member of the Responsible Brand, discuss student loan myths and misconceptions. Stanley shares his journey into the financial services industry, highlighting how mentorship and a passion for helping others led him to specialize in college planning and student debt management. With over 15 years of experience, he emphasizes the importance of understanding financial options for paying for college and the common challenges families face with student loans.

In the current landscape of higher education financing, student loan debt is often viewed as a burden solely borne by students. However, as Stanley Targosz highlights in the podcast episode, this perspective is misleading. The reality is that student loan debt is a family issue, with nearly equal amounts of debt held by both parents and students.

According to Targosz, the staggering total of $1.8 trillion in college debt is almost evenly split between parents and students. While students are indeed taking on significant loans, parents are also heavily involved in financing their children’s education, often through Parent PLUS loans or other forms of borrowing. Targosz predicts that in the next decade, the amount of debt held by parents may surpass that of students, further emphasizing the shared nature of this financial challenge.

A common misconception is that students should be able to navigate their college financing independently, as many parents did in their own youth. Targosz points out that this belief is flawed; the financial landscape has changed dramatically. For instance, if a student were to pay for their own college education solely through work, they would need to work 40 hours a week at a job that pays more than minimum wage. This scenario is unrealistic, as it would leave little time for academic responsibilities and personal well-being.

The implications of this shared debt are profound. When students struggle to make loan payments, it doesn’t just affect them; it also impacts their parents, especially if the loans are in the parents’ names. Targosz notes that many families find themselves in a precarious situation where the financial strain of student loans can lead to long-term consequences, such as delaying retirement or even having Social Security checks garnished to cover loan payments.

Given the shared nature of student loan debt, Targosz emphasizes the importance of family involvement in the planning and decision-making process. Parents need to be engaged from the beginning, understanding the financial commitments involved and working together with their children to create a sustainable plan. This collaborative approach can help families avoid the pitfalls of excessive debt and ensure that both parents and students are aligned regarding their financial futures.

In conclusion, student loan debt is not just a student issue; it is a family issue that requires collective awareness and action. By recognizing the shared responsibility and working together, families can navigate the complexities of college financing more effectively, ultimately leading to better outcomes for both parents and students.

Stanley shared: “Families often struggle with managing debt during their life seasons. I have been very successful at sharing ways to use internal savings to fund life’s events without taking away from big goals like college, retirement, or helping others. We all make the best decisions we can with the information we have at the time, my job is to give better information to help make better decisions moving forward. our goal is to use our God given skills and talents to serve others, not debt.”

Stanley also discusses the alarming trend of older adults still making student loan payments, with some even having their Social Security checks garnished. This underscores the importance of addressing student loan debt responsibly and ensuring that it does not become a lifelong burden.

Video Link: https://www.youtube.com/embed/G4D9USWNy50

About Stanley Targosz

As the President and Founder of The Responsible Brand, Stanley is dedicated to bringing financial education back to families and the industry. He believes that responsible solutions begin with a knowledge base that can be applied to each phase of life, helping individuals have more control over their current and future financial decisions. With over 20 years of experience in helping families understand how to afford the next step after high school without affecting their life goals, he also solves the extreme college debt issue organically, using a knowledge-based solution that everyone can implement. His mission is to put the family at the center of the solution, ensuring everyone wins.

Learn more: https://theresponsiblebrand.com/

Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Alopecia Areata pipeline constitutes 18+ key companies continuously working towards developing 20+ Alopecia Areata treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Alopecia Areata Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Alopecia Areata Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alopecia Areata Market.

Some of the key takeaways from the Alopecia Areata Pipeline Report:

Companies across the globe are diligently working toward developing novel Alopecia Areata treatment therapies with a considerable amount of success over the years.
Alopecia Areata companies working in the treatment market are Concert Pharmaceutical, Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, Chipscreen Biosciences, Forte Biosciences, HCW Biologics, Reistone Biopharma Company, Suzhou Zelgen Biopharmaceuticals, and others, are developing therapies for the Alopecia Areata treatment

Emerging Alopecia Areata therapies in the different phases of clinical trials are- CS 12192, FB-102, HCW 9302, ANB030, LP-0133, LH-8, SHR0302, Jaktinib, CTP-543, and others are expected to have a significant impact on the Alopecia Areata market in the coming years.
In March 2025, Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) have announced late-breaking results from the Phase 3 BRAVE-AA-PEDS study, showing that adolescents (ages 12 to under 18) with severe alopecia areata (AA) experienced significant hair regrowth on the scalp, eyebrows, and eyelashes after 36 weeks of once-daily oral treatment with baricitinib at 4 mg and 2 mg doses. These findings were presented during a late-breaker session at the American Academy of Dermatology (AAD) Annual Meeting.
In February 2025, Q32 Bio halted its Phase II trial for ADX-097, a former lead candidate for renal disease, as the company shifts its strategic focus to developing bempikibart for alopecia areata. Amid corporate restructuring and workforce reductions, the U.S.-based firm confirmed the cancellation of its Phase II renal basket trial (NCT06419205) and now plans to launch an open-label extension of its ongoing Phase II SIGNAL-AA trial (NCT06018428).
In January 2025, Eirion Therapeutics Inc., a biopharmaceutical company dedicated to advancing innovative prescription products in aesthetics, announced positive outcomes from its first-in-human clinical trial of ET-02, a topical pharmaceutical developed for the treatment of androgenic alopecia (age-related hair loss).
In July 2024, Sun Pharmaceutical Industries obtained approval from the US Food and Drug Administration (FDA) for LEQSELVI (deuruxolitinib), a treatment designed for managing an autoimmune disorder in adults.

Alopecia Areata Overview

Alopecia Areata is an autoimmune disorder characterized by sudden, non-scarring hair loss on the scalp, face, and sometimes other areas of the body. The condition occurs when the immune system mistakenly attacks hair follicles, causing hair to fall out in small, round patches. In some cases, it can lead to more extensive hair loss.

Get a Free Sample PDF Report to know more about Alopecia Areata Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/alopecia-areata-pipeline-insight

Emerging Alopecia Areata Drugs Under Different Phases of Clinical Development Include:

CS 12192: Chipscreen Biosciences
FB-102: Forte Biosciences
HCW 9302: HCW Biologics
Deuruxolitinib: Concert Pharmaceuticals
EQ101: Equillium
MAX 40070: Maxinovel Pharmaceuticals
ANB030: AnaptysBio
LP-0133: LEO Pharma
LH-8: Legacy Healthcare
SHR0302: Reistone Biopharma Company
Jaktinib: Suzhou Zelgen Biopharmaceuticals
CTP-543: Concert Pharmaceutical

Route of Administration

Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Molecule Type

Products have been categorized under various Molecule types, such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Alopecia Areata Pipeline Therapeutics Assessment

Alopecia Areata Assessment by Product Type
Alopecia Areata By Stage and Product Type
Alopecia Areata Assessment by Route of Administration
Alopecia Areata By Stage and Route of Administration
Alopecia Areata Assessment by Molecule Type
Alopecia Areata by Stage and Molecule Type

DelveInsight’s Alopecia Areata Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Alopecia Areata product details are provided in the report. Download the Alopecia Areata pipeline report to learn more about the emerging Alopecia Areata therapies

Some of the key companies in the Alopecia Areata Therapeutics Market include:

Key companies developing therapies for Alopecia Areata are – Aclaris Therapeutics, Concert Pharmaceuticals, Pfizer, Bristol Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Galderma, Regeneron Pharmaceuticals, Kythera Biopharmaceuticals, Cipla Ltd., Histogen, Allergan, Cassiopea S.p.A., Berg LLC, Follica, Inc., Stemson Therapeutics, RepliCel Life Sciences Inc., Kyocera Corporation, and others.

Alopecia Areata Pipeline Analysis:

The Alopecia Areata pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Alopecia Areata with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alopecia Areata Treatment.
Alopecia Areata key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Alopecia Areata Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alopecia Areata market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Alopecia Areata drugs and therapies

Alopecia Areata Pipeline Market Drivers

Increasing in the number of cases of alopecia areata, increasing Research and Development activities in Alopecia treatment are some of the important factors that are fueling the Alopecia Areata Market.

Alopecia Areata Pipeline Market Barriers

However, lack of approved therapies to treat alopecia Areata, side effects associated with the current treatment options and other factors are creating obstacles in the Alopecia Areata Market growth.

Scope of Alopecia Areata Pipeline Drug Insight

Coverage: Global
Key Alopecia Areata Companies: Concert Pharmaceutical, Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, Chipscreen Biosciences, Forte Biosciences, HCW Biologics, Reistone Biopharma Company, Suzhou Zelgen Biopharmaceuticals, and others
Key Alopecia Areata Therapies: CS 12192, FB-102, HCW 9302, ANB030, LP-0133, LH-8, SHR0302, Jaktinib, CTP-543, and others
Alopecia Areata Therapeutic Assessment: Alopecia Areata current marketed and Alopecia Areata emerging therapies
Alopecia Areata Market Dynamics: Alopecia Areata market drivers and Alopecia Areata market barriers

Request for Sample PDF Report for Alopecia Areata Pipeline Assessment and clinical trials

Table of Contents

1	Alopecia Areata Report Introduction
2	Alopecia Areata Executive Summary
3	Alopecia Areata Overview
4	Alopecia Areata- Analytical Perspective In-depth Commercial Assessment
5	Alopecia Areata Pipeline Therapeutics
6	Alopecia Areata Late Stage Products (Phase II/III)
7	Alopecia Areata Mid Stage Products (Phase II)
8	Alopecia Areata Early Stage Products (Phase I)
9	Alopecia Areata Preclinical Stage Products
10	Alopecia Areata Therapeutics Assessment
11	Alopecia Areata Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Alopecia Areata Key Companies
14	Alopecia Areata Key Products
15	Alopecia Areata Unmet Needs
16	Alopecia Areata Market Drivers and Barriers
17	Alopecia Areata Future Perspectives and Conclusion
18	Alopecia Areata Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp

Paws and Passport Launches ‘My Little Love,’ a Heartwarming Tribute to Pet Parenthood

California, USA – May 01, 2025 – Paws and Passport, LLC, an organization working to empower pet parents, has announced the release of its debut book, “My Little Love”. This nonfiction tribute reflects the unconditional bond between pets and their owners in terms of much-needed joys, including issues and the remarkable love shared with animal companions.

As the first release by Paws and Passport, “My Little Love” underlines the company’s role towards committing insightful content on pet parenting, a guide to their audience, with care and knowledge, for their journey with their pets. The book is targeted at pet lovers collaborating against people who understand how much humans love their pets.

The author of the book “My Little Love,” Jude Laurén, shares her most personal experiences of being a devoted pet parent to Buster, the Shih Tzu who changed her life. Sooner or later, every reader becomes an ardent admirer of Buster, whose serendipitous meeting with the author filled her life with love and laughter. Jude, deeply involved in every chapter of this book, pours her love and passion into nurturing this unique connection with animals. Speaking on the birth of “My Little Love,” Jude said, “Buster taught me about unconditional love in ways I never imagined. This book honours the remarkable pets who have imprinted their paw prints on our hearts. It celebrates their presence and the joy they bring into our lives.”

Paws and Passport was founded on a clear mission: to provide pet parents with well-researched content that enriches the human animal bond. With “My Little Love”, the company aims to serve as a go-to hub for nonfiction content on pet care and products meant to improve pets’ quality of life alongside their owners.

“My Little Love” emphasizes a message beyond pet care and into the universal concept of unconditional love. The book focuses on resonating with the experience and connection of most people who have ever owned pets and have deeply loved them. Jude Laurén’s true storytelling about the relationship between pets and their humans makes this book a must-read for pet lovers and parents.

Beyond a memoir of Jude’s journey with Buster, the book also reflects on the vital role pets play in our lives. As Jude finely captures, “Our pets are our family, our companions, and sometimes our best friends. They give us so much without asking for anything in return. This book is a celebration of that unconditional love.”

“My Little Love” is now readily available for purchase on the Paws and Passport website and in major book retailers. Readers and pet owners can easily get their hands on this insightful book, which reminds readers of the importance of cherishing every moment with their pets and the unique bond they share.

About Paws and Passport

Paws and Passport is a publishing house dedicated to pet parents and animal lovers. It offers thoughtful, well-researched nonfiction books, fiction books, and pet products carefully curated to enhance the lives of pets and their owners. Pursuing a mission that focuses on enabling pet parents, Paws and Passport strives to be the trusted source of knowledge about pet care and much more.

Media Contact
Company Name: Paws and Passport LLC
Contact Person: Jude Lauren
Email: Send Email
Phone: 949-687-7676
Country: United States
Website: https://mylittlelove.us/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Paws and Passport Launches ‘My Little Love,’ a Heartwarming Tribute to Pet Parenthood

Stanley Howard Freeman Unveils Comprehensive Guide to Understanding Cancer in His Latest Book

Stanley Howard Freeman’s latest work, “27 Cancers,” delivers a complete overview of many types of cancer, intending to educate and empower readers. As medical developments grow quickly, this book is a vital source for the general public and healthcare professionals. With a pleasing writing style, Freeman digs into 27 distinct forms of cancer, providing an understanding of their causes, symptoms, diagnostic methods, treatment options, and protective measures.

Stanley Howard Freeman is an esteemed expert in pharmacy and healthcare, with extensive experience of more than three decades in several roles, including Chairman of the Department of Pharmacy and Director of Clinical Trials. He has contributed meaningfully to the sector through available language and well-researched information. As a member of the American Cancer Society, he endeavours to update and empower people, which makes his book “27 Cancers” a worthy asset for patients and caregivers.

The book starts with an introduction to cancer, talking about its pervasive effect on society and the emotional toll it takes on people and families. Freeman stresses the importance of awareness and early discovery, which demonstrates how timely interference can meaningfully improve outcomes. Each section of the book is accurately composed, focusing on specific cancers such as Acute Myeloid Leukaemia (AML), Biliary Tract Cancer (BTC), Acute Lymphoblastic Leukaemia (ALL), Breast Cancer, Bladder Cancer, and Cervical Cancer.

In the section on Acute Lymphoblastic Leukaemia (ALL), Freeman discusses the genetic and environmental danger elements, signs, and diagnostic procedures involved. He also discourses treatment options that include chemotherapy and stem cell transplantation while emphasizing the importance of tailored treatment tactics. The following chapters shadow a similar structure, delivering readers a distinct know-how of different cancer types and their rare characteristics, and the latest readers a clear understanding of each cancer type, its unique characteristics, and the latest treatment advancements.

Freeman’s strategy is methodical and compassionate. He knows the fear and stigma related to cancer and intends to clarify the subject through accurate information and realistic advice. His writing is available, which makes complicated medical concepts clear to readers without a technical background. This convenience is vital in delivering a more well-versed public that can engage in debates about health and wellness.

Moreover, Freeman’s wide research is underlined by references to current studies and statistical data, strengthening the trustworthiness of the information presented. He inspires readers to take an energetic role in their health by recognizing symptoms and seeking quick medical attention. This practical approach to health management is a recurring element throughout the book.

Freeman’s book “27 Cancers” is a prompt for implementation for people to prefer their health and comfort. By shedding light on the importance of cancer, he intends to cultivate a more informed and proactive society. “27 Cancers” by Stanley Howard Freeman is an indispensable read to deepen their knowledge of this serious health issue. The book’s informative focus delivers a valuable resource for dealing with the often-overwhelming situation of cancer diagnosis and treatment. Freeman’s work is proof of his dedication to enhancing public health and providing people with the information they require to make well-versed decisions related to their well-being.

Media Contact
Company Name: Dan Brown Academy
Contact Person: Jeff Jones
Email: Send Email
Country: United States
Website: https://drstanleyfreeman.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stanley Howard Freeman Unveils Comprehensive Guide to Understanding Cancer in His Latest Book

Beta Thalassemia Market Set to Grow Substantially Through 2034, DelveInsight Projects | Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma, Bristol-Myers

The Key Beta Thalassemia Companies in the market include – Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others.

DelveInsight’s “Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Beta Thalassemia, historical and forecasted epidemiology as well as the Beta Thalassemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Beta Thalassemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Beta Thalassemia Market Forecast

Some of the key facts of the Beta Thalassemia Market Report:

The Beta Thalassemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In January 2025, Agios Pharmaceuticals (AGIO) announced that the FDA has accepted its supplemental new drug application (sNDA) to expand the label of Pyrukynd, its sole marketed drug, to include the treatment of thalassemia.
In January 2025, YolTech Therapeutics is preparing to launch a clinical trial for YOLT-204, its in vivo gene-editing therapy designed to treat transfusion-dependent beta-thalassemia (TDT). TDT is a genetic blood disorder caused by mutations in the beta-globin gene, leading to reduced or absent hemoglobin production. Patients with this condition require regular blood transfusions to manage anemia and prevent future complications.
In 2023, the Beta-thalassemia market size in the US was around USD 358 million, with expectations of significant growth by 2034, driven by a substantial Compound Annual Growth Rate (CAGR) during the study period (2020–2034).
The Beta-thalassemia market size in EU4 and the UK was around USD 356 million and is anticipated to grow during the forecast period.
Among European countries, Italy had the largest Beta-thalassemia market size, reaching approximately USD 241 million in 2023.
The Beta-thalassemia market size in the EU4 and the UK was roughly USD 356 million, with projections indicating further growth during the forecast period.
Italy had the largest Beta-thalassemia market size among European countries, reaching around USD 241 million in 2023.
In September 2023, Pharmacosmos initiated a Phase IItrial of SP-420 in patients with transfusion-dependent β-thalassemia.
In June 2023, FDA accepted the Biologics License Application (BLAs) of exagamglogene autotemcel (exa-cel) for transfusion dependent beta thalassemia (TDT). The Prescription Drug User FeeAct (PDUFA) target action date for TDT is March 30, 2024.
The Centers for Disease Control and Prevention (2023) state that beta thalassemia is comparatively uncommon in the US
In 2023, the United States had 1,359,000 prevalent cases of Beta-thalassemia Minor. These numbers are anticipated to change considerably by 2034.
Germany had approximately 235,000 prevalent cases of Beta-thalassemia Minor in 2023.
In the UK, a significant difference was seen in the prevalence of Beta-thalassemia types, with Beta Thalassemia Major being more common than Beta Thalassemia Intermedia. In 2023, there were about 745,000 cases of Beta-thalassemia Major recorded, and these numbers are anticipated to fluctuate further during the study period from 2020 to 2034.
Italy had the highest number of prevalent Beta-thalassemia minor cases among the EU4 countries and the UK, with approximately 3,676,000 cases, followed by Spain with around 772,000 cases. These numbers are projected to change significantly by 2034.
In 2023, France had approximately 678,000 diagnosed prevalent cases of Beta-thalassemia, with these numbers anticipated to change further by 2034.
Key Beta Thalassemia Companies: Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others
Key Beta Thalassemia Therapies: PYRUKYND (mitapivat), CTX001, SP-420, EDIT-301, dimethylbutyrate, ACE-536, Luspatercept, Bitopertin, Deferitrin (GT56-252), ICL670, Emeramide, SP-420, Luspatercept, DST-0509, Mitapivat, SPD602, and others
The Beta Thalassemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Beta Thalassemia pipeline products will significantly revolutionize the Beta Thalassemia market dynamics.

Beta Thalassemia Overview

Beta thalassemia is a genetic blood disorder characterized by reduced or absent production of hemoglobin beta chains, leading to abnormal red blood cells. This results in anemia, fatigue, and other complications due to insufficient oxygen delivery throughout the body. Beta thalassemia can range from mild to severe, with the severe form, known as thalassemia major, requiring regular blood transfusions and iron chelation therapy to manage iron overload. The condition is inherited in an autosomal recessive manner, and while there is no universal cure, treatments focus on managing symptoms and preventing complications. Stem cell or bone marrow transplants offer potential cures for certain cases.

Get a Free sample for the Beta Thalassemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/beta-thalassemia-market

Beta Thalassemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Beta Thalassemia Epidemiology Segmentation:

The Beta Thalassemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Beta Thalassemia
Prevalent Cases of Beta Thalassemia by severity
Gender-specific Prevalence of Beta Thalassemia
Diagnosed Cases of Episodic and Chronic Beta Thalassemia

Download the report to understand which factors are driving Beta Thalassemia epidemiology trends @ Beta Thalassemia Epidemiology Forecast

Beta Thalassemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Beta Thalassemia market or expected to get launched during the study period. The analysis covers Beta Thalassemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Beta Thalassemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Beta Thalassemia Therapies and Key Companies

PYRUKYND (mitapivat): Agios Pharmaceuticals
CTX001: Vertex Pharmaceuticals
SP-420: Pharmacosmos
EDIT-301: Editas Medicine
dimethylbutyrate: HemaQuest Pharmaceuticals
ACE-536: Acceleron Pharma
Luspatercept: Bristol-Myers Squibb
Bitopertin: Hoffmann-La Roche
Deferitrin (GT56-252): Sanofi
ICL670: Novartis
Emeramide: EmeraMed
SP-420: Pharmacosmos A/S
Luspatercept: Celgene
DST-0509: DisperSol Technologies, LLC
Mitapivat: Agios Pharmaceuticals
SPD602: Shire

Discover more about therapies set to grab major Beta Thalassemia market share @ Beta Thalassemia Treatment Market

Beta Thalassemia Market Strengths

Strong pipeline activity with potential Phase III and phase II emerging therapies.
Increasing prevalence and awareness of beta thalassemia

Beta Thalassemia Market Opportunities

Lack of any curative treatment options despite the launch of gene therapies which are subject to patient outcome assessment
Improved national blood policies
Advancement in genetic engineering because gene therapy has been hypothesized to serve as an effective cure for monogenic blood disorders for several decades

Scope of the Beta Thalassemia Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Beta Thalassemia Companies: Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others
Key Beta Thalassemia Therapies: PYRUKYND (mitapivat), CTX001, SP-420, EDIT-301, dimethylbutyrate, ACE-536, Luspatercept, Bitopertin, Deferitrin (GT56-252), ICL670, Emeramide, SP-420, Luspatercept, DST-0509, Mitapivat, SPD602, and others
Beta Thalassemia Therapeutic Assessment: Beta Thalassemia current marketed and Beta Thalassemia emerging therapies
Beta Thalassemia Market Dynamics: Beta Thalassemia market drivers and Beta Thalassemia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Beta Thalassemia Unmet Needs, KOL’s views, Analyst’s views, Beta Thalassemia Market Access and Reimbursement

To know more about Beta Thalassemia companies working in the treatment market, visit @ Beta Thalassemia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Beta Thalassemia Market Report Introduction

2. Executive Summary for Beta Thalassemia

3. SWOT analysis of Beta Thalassemia

4. Beta Thalassemia Patient Share (%) Overview at a Glance

5. Beta Thalassemia Market Overview at a Glance

6. Beta Thalassemia Disease Background and Overview

7. Beta Thalassemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Beta Thalassemia

9. Beta Thalassemia Current Treatment and Medical Practices

10. Beta Thalassemia Unmet Needs

11. Beta Thalassemia Emerging Therapies

12. Beta Thalassemia Market Outlook

13. Country-Wise Beta Thalassemia Market Analysis (2020–2034)

14. Beta Thalassemia Market Access and Reimbursement of Therapies

15. Beta Thalassemia Market Drivers

16. Beta Thalassemia Market Barriers

17. Beta Thalassemia Appendix

18. Beta Thalassemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Beta Thalassemia Market Set to Grow Substantially Through 2034, DelveInsight Projects | Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma, Bristol-Myers

“Wild Unbreakable” by Night X Dreamz Crowned the Album of the Summer – Now Streaming Everywhere

Turn up the volume — summer has a soundtrack, and it’s Wild Unbreakable, the electrifying new album by Night X Dreamz, now available on all major streaming platforms.

Packed with dance-floor bangers, late-night anthems, and empowering lyrics, Wild Unbreakable is a 13-track thrill ride designed to make you feel alive. From rooftop parties to solo escapes, this album captures every season’s mood with undeniable heat.

Led by the viral hit “Hot Girl Summer” and the hypnotic “Chasing Stars,” Night X Dreamz delivers a genre-defying fusion of pop, electro, and futuristic soul, creating a fearless sound that celebrates individuality and freedom.

Stream it on Apple Music https://music.apple.com/us/album/wild-unbreakable/1807877051

on Amazon https://music.amazon.com/artists/B0F4FTG5L6/night-x-dreamz

on Spotify https://open.spotify.com/album/3i4u5NX2VWNFDMpIXavEDN and

on YouTube https://www.youtube.com/watch?v=HWNXl3ojlLY&list=OLAK5uy_koQHqqYr6Hu2nm6IWRrRpsp1CG7XVOfHo today.

Full Track Listing:

Chasing Stars
Hot Girl Summer
Midnight Secrets
Viral Queen
Bounce It
Mirror Mirror
Wild Side
Violet Skies
9 to 5
Sugar Rush
Till the Break of Dawn
Storms
Wild Unbreakable

“This album is a love letter to living out loud,” says Night X Dreamz. “It’s about owning your power, your pleasure, and your unapologetically.”

With its mix of shimmering beats, addictive hooks, and fearless lyrics, Wild Unbreakable is not just music — it’s a vibe. Whether driving with the top down or dancing under neon lights, this is the soundtrack your summer needs.

Stream Wild Unbreakable on Spotify, Apple, Amazon, Tidal, and YouTube.

Media Contact
Company Name: ITunes Exposure
Contact Person: James Moore
Email: Send Email
City: Chicago
State: IL
Country: United States
Website: www.itunesexposure.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: “Wild Unbreakable” by Night X Dreamz Crowned the Album of the Summer – Now Streaming Everywhere